Three RSV vaccines are now approved for older adults in the United States, marking a significant shift in how we protect aging populations from a virus that hospitalizes an estimated 100,000 to 150,000 Americans over 60 every year. GSK’s Arexvy, Pfizer’s Abrysvo, and Moderna’s mResvia each received FDA approval between 2023 and 2024, and all three have since expanded their approved age ranges to include younger at-risk adults. For caregivers and families navigating dementia care, where respiratory infections can trigger rapid cognitive and physical decline, these vaccines represent a concrete tool for reducing preventable hospitalizations. The most recent development came on March 13, 2026, when the FDA approved GSK’s Arexvy for adults aged 18 to 49 who face increased risk of RSV lower respiratory tract disease.
That expansion followed similar moves by Pfizer and Moderna to broaden their vaccines beyond the initial 60-and-older population. For anyone caring for a loved one with dementia or other neurological conditions, understanding which vaccine options exist, who qualifies, and what the CDC currently recommends is essential for making informed decisions during the next respiratory season. This article walks through each approved RSV vaccine, how they compare, what the clinical data actually shows, and why RSV prevention matters so much in the context of brain health and cognitive decline. We also cover the CDC’s updated recommendations, practical considerations for caregivers, and what limitations remain.
Table of Contents
- Which RSV Prevention Vaccines Are Approved for Older Adults and How Do They Work?
- Why RSV Poses a Serious Threat to People With Dementia and Cognitive Decline
- How the FDA’s Expanded Approvals Changed Who Can Get Vaccinated
- What Does the CDC Recommend and How Should Caregivers Decide?
- Limitations of RSV Vaccines That Caregivers Should Know
- RSV Prevention in Long-Term Care and Memory Care Facilities
- What Comes Next for RSV Prevention
- Conclusion
- Frequently Asked Questions
Which RSV Prevention Vaccines Are Approved for Older Adults and How Do They Work?
All three approved RSV vaccines target the prefusion form of the RSV F protein, the structure the virus uses to enter human cells. By training the immune system to recognize and neutralize this protein before the virus can take hold, these vaccines reduce the risk of lower respiratory tract disease, the severe form of RSV infection that drives hospitalizations and deaths. GSK’s arexvy was the first to cross the finish line, receiving FDA approval in May 2023 for adults aged 60 and older. Pfizer’s Abrysvo followed shortly after, also approved in 2023 for the same age group. Moderna’s mResvia, which uses mRNA technology similar to its COVID-19 vaccine, received approval in 2024.
Each vaccine takes a slightly different approach. Arexvy and Abrysvo are protein-based vaccines, while mResvia delivers mRNA instructions that prompt the body to produce the prefusion F protein on its own. In clinical trials, Moderna’s mResvia demonstrated a vaccine efficacy of 82.4 percent against RSV lower respiratory tract disease defined by three or more symptoms, a strong result that contributed to its expanded approval for younger at-risk adults in 2025. All three vaccines have shown non-inferior immune responses when tested in younger populations compared to the original 60-and-older trial groups, which is what allowed the FDA to extend their indications. A key comparison worth noting: Pfizer’s Abrysvo now holds the broadest indication of the three, approved for adults aged 18 and older at increased risk, and it carries the unique additional approval for maternal immunization in pregnant individuals at 32 to 36 weeks gestation to protect newborns. For families where multiple generations may be at risk, that dual indication sets Abrysvo apart, though the choice of vaccine should always involve a conversation with a healthcare provider about individual risk factors.
Why RSV Poses a Serious Threat to People With Dementia and Cognitive Decline
RSV is often dismissed as a childhood illness, but in older adults it can be devastating. Adults hospitalized with RSV are more likely to require ICU care and mechanical ventilation compared to those hospitalized with influenza or COVID-19. The virus causes an estimated economic burden of over 1.5 billion dollars annually in the United States, and among those over 60, it drives roughly 100,000 to 150,000 hospitalizations each year. These are not mild cases. For someone already living with Alzheimer’s disease or another form of dementia, a hospitalization of this severity can accelerate cognitive decline in ways that are difficult or impossible to reverse. Hospitalization itself is a well-documented risk factor for worsening dementia.
Delirium, which frequently accompanies severe respiratory infections in older adults, can cause a sudden and lasting drop in cognitive function. A person with mild cognitive impairment who enters the hospital with RSV may leave with significantly worse memory, orientation, and functional ability. The disruption to routine, the unfamiliar environment, sedating medications, and the physical toll of fighting a serious infection all compound the damage. Prevention, rather than treatment after the fact, is where the real opportunity lies. However, if your loved one has a history of severe allergic reactions to vaccine components, or if they have a condition like Guillain-Barré syndrome in their medical history, vaccination may not be appropriate without careful medical review. The most common side effects across all three vaccines are relatively mild, including injection site pain, fatigue, muscle aches, headache, and joint pain, but individual risk assessment matters. This is especially true for people taking immunosuppressive medications or those with complex medication regimens common in dementia care.
How the FDA’s Expanded Approvals Changed Who Can Get Vaccinated
The original approvals in 2023 and 2024 limited RSV vaccines to adults aged 60 and older, leaving a significant gap. An estimated 21 million adults under 50 in the United States have at least one risk factor for severe RSV infection, including conditions like coronary artery disease, congestive heart failure, chronic lung disease, and diabetes. Among adults aged 18 to 49 alone, RSV causes approximately 17,000 hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits annually. Those numbers make clear that RSV is not just a problem for the elderly. The expanded approvals addressed this gap. Moderna received FDA approval in 2025 to offer mResvia to adults aged 18 to 59 at increased risk.
Its Phase 3 trial specifically enrolled adults with underlying conditions and demonstrated strong efficacy. GSK’s Arexvy expansion in March 2026 was supported by a Phase IIIb trial of 426 at-risk adults aged 18 to 49, who showed immune responses that were non-inferior to those seen in 429 adults aged 60 and older. The primary endpoints measured RSV-A and RSV-B neutralization titres at one month post-vaccination. Pfizer’s Abrysvo similarly expanded to cover adults aged 18 to 59 at increased risk. For dementia caregivers, this expansion matters in a practical way. If you are a younger adult providing daily hands-on care for a parent or spouse with dementia, and you have an underlying health condition like asthma or diabetes, you may now qualify for an RSV vaccine yourself. Protecting the caregiver is one of the most effective ways to protect the care recipient, particularly in home care settings where close contact is unavoidable.
What Does the CDC Recommend and How Should Caregivers Decide?
The CDC updated its RSV vaccination recommendations in June 2024. The current guidance is straightforward: a single dose of an RSV vaccine is recommended for all adults aged 75 and older. For adults aged 60 to 74, the vaccine is recommended if they have risk factors for severe disease. These risk factors include chronic heart or lung disease, weakened immune systems, residence in a nursing home or long-term care facility, and other conditions that increase vulnerability to respiratory infections. When deciding between the three vaccines, the differences are more about availability and your provider’s familiarity than about dramatic variations in effectiveness.
All three have demonstrated strong immune responses in clinical trials. Moderna’s mResvia showed 82.4 percent efficacy against RSV lower respiratory tract disease with three or more symptoms, which is the most specific efficacy figure publicly available among the three. However, head-to-head trials comparing the vaccines directly have not been conducted, so claims that one is definitively superior to another are not supported by current evidence. The tradeoff with mResvia’s mRNA platform is that some patients and providers are more comfortable with protein-based vaccines like Arexvy or Abrysvo, while others may prefer the mRNA approach based on their experience with COVID-19 vaccination. For a person with moderate to advanced dementia, the decision to vaccinate should involve their primary care physician and, where applicable, their legal health care proxy. The conversation should weigh the individual’s overall health status, their exposure risk based on living situation, and whether the mild side effects like fatigue and muscle aches could cause distress or behavioral changes in someone who may not understand why they feel unwell.
Limitations of RSV Vaccines That Caregivers Should Know
No vaccine is perfect, and the RSV vaccines have limitations worth understanding. First, the CDC recommends a single dose rather than annual revaccination, but the duration of protection is still being studied. It remains uncertain how long immunity lasts and whether booster doses will eventually be needed, particularly for immunocompromised individuals whose initial immune response may be weaker. If your loved one received an RSV vaccine in 2023 or 2024, talk to their doctor about whether additional protection may be warranted in future seasons. Second, these vaccines reduce the risk of severe lower respiratory tract disease, but they do not prevent RSV infection entirely.
A vaccinated person can still contract RSV and experience upper respiratory symptoms. In a dementia care setting, even a mild respiratory illness can disrupt sleep, appetite, and medication adherence, leading to behavioral changes that caregivers must manage. Vaccination is one layer of protection, not a replacement for other infection control practices like hand hygiene, limiting exposure during peak RSV season (typically fall through spring), and keeping living spaces well-ventilated. Third, the clinical trials for expanded age indications used immunogenicity endpoints, meaning they measured antibody levels rather than directly measuring real-world disease prevention in younger populations. While non-inferior immune responses strongly suggest comparable protection, the evidence base is not identical to the large efficacy trials conducted in older adults. This is a standard regulatory approach and not a cause for alarm, but it is a nuance that informed caregivers should be aware of when evaluating the strength of the evidence.
RSV Prevention in Long-Term Care and Memory Care Facilities
Nursing homes and memory care facilities are particularly vulnerable to RSV outbreaks. Residents live in close quarters, share common spaces, and often rely on staff who move between multiple rooms throughout the day. A single RSV case can spread rapidly through a facility, and for residents with dementia who may not be able to articulate symptoms like sore throat or chest tightness, the infection can progress significantly before it is identified.
Vaccination of both residents and staff is the most effective institutional-level prevention strategy. Some long-term care facilities have begun incorporating RSV vaccination into their fall immunization protocols alongside influenza and COVID-19 vaccines. If your loved one lives in a care facility, it is worth asking the facility’s medical director whether RSV vaccination is offered and, if so, which vaccine they use. If it is not yet part of their protocol, requesting it and providing the CDC’s recommendation as a reference can help move the conversation forward.
What Comes Next for RSV Prevention
The RSV vaccine landscape is likely to continue evolving. Researchers are investigating whether combination vaccines that protect against RSV, influenza, and COVID-19 in a single shot could simplify the increasingly crowded fall vaccination schedule for older adults. Moderna has combination candidates in its pipeline, and other manufacturers are exploring similar approaches.
For dementia patients and their caregivers, fewer injections and fewer clinic visits would be a meaningful practical improvement. There is also growing interest in whether RSV vaccination could have indirect cognitive benefits by reducing the hospitalizations and delirium episodes that are known to accelerate dementia progression. No study has directly tested this hypothesis yet, but the logic is sound: if vaccination prevents even a fraction of the severe respiratory infections that lead to hospitalization, it may help preserve cognitive function over time. That possibility alone makes RSV vaccination a topic that belongs firmly in the conversation about comprehensive dementia care planning.
Conclusion
RSV is no longer a virus that older adults and their caregivers have to simply endure each winter. Three FDA-approved vaccines, Arexvy, Abrysvo, and mResvia, now provide real options for reducing the risk of severe respiratory disease in adults aged 60 and older, with expanded approvals extending protection to younger at-risk adults as well. The CDC recommends vaccination for all adults 75 and older and for those 60 to 74 with risk factors, making eligibility broad enough to cover most people in dementia care settings.
For caregivers managing the complex needs of someone with cognitive decline, adding RSV vaccination to the care plan is a concrete, evidence-based step that can help avoid the kind of hospitalizations that worsen dementia outcomes. Talk to your loved one’s physician about which vaccine is available, whether the timing aligns with other seasonal immunizations, and what to expect in terms of mild side effects. Prevention is always easier than recovery, and for people living with dementia, recovery from a serious respiratory illness may never be complete.
Frequently Asked Questions
Are RSV vaccines safe for people with Alzheimer’s disease or other forms of dementia?
The RSV vaccines have not been specifically studied in dementia populations, but there is no medical reason why a dementia diagnosis alone would preclude vaccination. The common side effects, including injection site pain, fatigue, and muscle aches, are generally mild. Discuss any concerns with the individual’s physician, especially if they are on blood thinners or immunosuppressive medications.
Can my loved one get an RSV vaccine at the same time as a flu shot or COVID-19 booster?
The CDC has not issued specific guidance against co-administration of RSV vaccines with other seasonal vaccines, and many providers are administering them during the same visit. However, receiving multiple vaccines at once may increase the likelihood of temporary side effects like fatigue. Ask the provider what their clinical judgment is based on the patient’s overall health.
How much does an RSV vaccine cost, and is it covered by insurance?
RSV vaccines are covered under Medicare Part D and most private insurance plans for adults who meet the CDC’s recommended criteria. Without insurance, the out-of-pocket cost can be several hundred dollars. Check with your pharmacy or provider’s office about coverage before scheduling.
Which RSV vaccine is the best one?
There is no head-to-head trial comparing the three vaccines directly, so no definitive answer exists. Moderna’s mResvia showed 82.4 percent efficacy against RSV lower respiratory tract disease with three or more symptoms in its clinical trial. All three have demonstrated strong immune responses. The best vaccine is the one available to you and recommended by your healthcare provider based on individual factors.
Does the RSV vaccine prevent infection entirely?
No. The vaccines are designed to reduce the risk of severe lower respiratory tract disease, not to prevent all RSV infection. A vaccinated person may still catch RSV and experience mild symptoms. The goal is to avoid the severe outcomes, particularly hospitalization and ICU admission, that pose the greatest danger to older adults and people with cognitive decline.
Is the RSV vaccine a one-time shot or do I need it every year?
The current CDC recommendation is for a single dose. Whether booster doses will be needed in the future is still under investigation. Researchers are studying the durability of the immune response, and guidance may be updated as more long-term data becomes available.
